糖尿病预防计划结局研究中微血管并发症相关的共享与独特代谢组学特征
在糖尿病预防计划结局研究(DPPOS)的1947名参与者中,随访15年时有572人发生至少一种微血管并发症(肾病277例、视网膜病变194例、神经病变212例)。研究应用bootstrapped LASSO方法分析353种注释代谢物,发现105种代谢物可预测任一并发症,其中74种仅预测一种、27种预测两种、4种预测三种。组氨酸、丝氨酸与较低肾病风险相关,丝氨酸还与较低神经病变风险相关;部分代谢物与治疗臂存在交互作用。
要点
- 组氨酸与较低肾病风险相关(OR 0.75;95% CI 0.69, 0.88)。
- 丝氨酸与较低肾病(OR 0.69;95% CI 0.58, 0.82)和神经病变(OR 0.68;95% CI 0.56, 0.84)风险相关。
- 二甲双胍臂中N-氨甲酰-β-丙氨酸与较高肾病风险相关(OR 1.99;95% CI 1.38, 2.99)。
核心结论
- 存在与单一微血管并发症相关的独特代谢物谱,提示除共享机制外需关注各并发症特异病理生理机制。
研究设计与样本
- 糖尿病预防计划结局研究(DPPOS)长期随访,纳入1947名参与者,随访15年。
- 应用bootstrapped LASSO分析353种注释代谢物,识别与一种或多种并发症相关的代谢物。
- 对命中代谢物检验与DPP治疗臂的交互作用,并运行多变量模型。
主要发现
- 随访时572名参与者发生至少一种并发症:肾病277例、视网膜病变194例、神经病变212例。
- 105种代谢物预测任一并发症,其中74种预测一种、27种预测两种、4种预测三种。
- 在无治疗臂交互的69种代谢物汇总分析中,组氨酸预测较低肾病风险(OR 0.75;95% CI 0.69, 0.88)。
- 丝氨酸预测较低肾病风险(OR 0.69;95% CI 0.58, 0.82)和较低神经病变风险(OR 0.68;95% CI 0.56, 0.84)。
- 36种代谢物与治疗臂交互:二甲双胍臂中N-氨甲酰-β-丙氨酸预测较高肾病风险(OR 1.99;95% CI 1.38, 2.99),C22:0-鞘磷脂预测较低神经病变风险(OR 0.54;95% CI 0.37, 0.77);生活方式干预臂中喹啉酸预测较高神经病变风险(OR 1.64;95% CI 1.24, 2.19)。
临床怎么用
- 代谢物谱可能有助于识别特定微血管并发症高风险个体,但需进一步验证。
- 组氨酸和丝氨酸等代谢物与较低并发症风险相关,提示潜在保护作用。
- 治疗臂特异性代谢物关联提示需考虑降糖干预方式对并发症风险的影响。
局限性
- 估计值已调整性别、种族、基线年龄、BMI和吸烟及随访时间,进一步调整HbA1c、 incident diabetes和eGFR未改变结果。
- 研究未明确报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this study was to identify shared and distinct metabolite profiles prospectively associated with nephropathy, retinopathy and neuropathy at 15 years' follow-up among 1947 participants in the Diabetes Prevention Program Outcomes Study, the long-term follow-up of the Diabetes Prevention Program (DPP). METHODS: We applied bootstrapped LASSO to 353 annotated metabolites to identify metabolites associated with one or more complication. For these metabolite hits, we tested for an interaction with DPP treatment arm, and ran multivariable models for the pooled sample or within treatment group as appropriate. RESULTS: At follow-up, 572 participants had one or more complication (n=277 nephropathy, n=194 retinopathy, n=212 neuropathy). Of 105 metabolites that predicted any complication, 74 predicted one, 27 predicted two, and four predicted all three. In a pooled analysis of 69 metabolites without treatment arm interactions, histidine predicted lower odds of nephropathy (OR 0.75; 95% CI 0.69, 0.88), and serine predicted lower odds of nephropathy (OR 0.69; 95% CI 0.58, 0.82) and neuropathy (OR 0.68; 95% CI 0.56, 0.84). Of 36 metabolites that interacted with treatment arm, higher N-carbamoyl-β-alanine predicted greater odds of nephropathy (OR 1.99; 95% CI 1.38, 2.99) and C22:0-sphingomyelin predicted lower odds of neuropathy (OR 0.54; 95% CI 0.37, 0.77) in the metformin arm. In the lifestyle intervention arm, quinolinic acid predicted greater odds of neuropathy (OR 1.64; 95% CI 1.24, 2.19). These estimates accounted for sex, race, baseline age, BMI and smoking, and time elapsed during follow-up. Further adjustment for HbA1c during follow-up, incident diabetes and eGFR did not change the results. CONCLUSIONS/INTERPRETATION: The existence of distinct metabolite profiles associated with single microvascular complications highlights the importance of characterising pathophysiological mechanisms specific to each complication, in addition to studying shared mechanisms across multiple complications.
引用
- Perng W, Shu S, Nathan DM, et al. Shared and distinct metabolomics profiles associated with microvascular complications in the Diabetes Prevention Program Outcomes Study. Diabetologia. 2025. PMID: 41074977. doi:10.1007/s00125-025-06571-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。